J Endocrinol Metab

Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access

Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc

Journal website http://www.jofem.org

Original Article

Volume 4, Number 1-2, April 2014, pages 25-31

Alteration in Lipid Profile in Treatment-Naive HIV-Infected Patients and Changes Following HAART Initiation in Haryana

Figure 1. Mean value of lipid profile in treatment-naive HIV-infected patients and after 3 and 6 months of follow-up.

**Table 1.** Lipid Profile of HIV-Positive Patients and Controls
Parameter	HIV-positive patients (n = 100)	HIV-negative controls (n = 100)	P value
Significant; *Highly significant; all values are in mean ± SD.
Triglyceride (mg/dL)	178.46 ± 58.41	136.26 ± 23.21	< 0.001**
Total cholesterol (mg/dL)	171.17 ± 52.24	175.09 ± 42.3	0.08
LDL cholesterol (mg/dL)	108.62 ± 38.67	98.62 ± 2.94	< 0.05*
VLDL cholesterol (mg/dL)	35.69 ± 11.76	27.25 ± 4.6	< 0.05*
HDL cholesterol (mg/dL)	26.86 ± 12.69	49.22 ± 34.76	< 0.001**

Table 1. Lipid Profile of HIV-Positive Patients and Controls

Parameter

HIV-positive patients (n = 100)

HIV-negative controls (n = 100)

P value

*Significant; **Highly significant; all values are in mean ± SD.

Triglyceride (mg/dL)

178.46 ± 58.41

136.26 ± 23.21

< 0.001**

Total cholesterol (mg/dL)

171.17 ± 52.24

175.09 ± 42.3

0.08

LDL cholesterol (mg/dL)

108.62 ± 38.67

98.62 ± 2.94

< 0.05*

VLDL cholesterol (mg/dL)

35.69 ± 11.76

27.25 ± 4.6

< 0.05*

HDL cholesterol (mg/dL)

26.86 ± 12.69

49.22 ± 34.76

< 0.001**

**Table 2.** Anthropometric and Biochemical Parameters of the HIV-Positive Patients
Parameter	Treatment-naive HIV-positive patients	3 months on HAART	P value	6 months on HAART	P value
Significant; *Highly significant; all values are in mean ± SD.
Number of patients	100	100	-	100	-
Weight (kg)	51.41 ± 9.95	54.14 ± 10.23	< 0.001**	54.78 ± 9.75	< 0.001**
BMI (kg/m²)	23.27 ± 4.21	24.21 ± 3.25	< 0.001**	25.61 ± 3.89	< 0.001**
Waist circumference (cm)	70.57 ± 7.88	72.29 ± 8.15	< 0.001**	72.97 ± 8.16	< 0.001**
Hip circumference (cm)	81.03 ± 7.34	81.95 ± 7.56	< 0.001**	82.04 ± 7.42	< 0.001**
Waist/hip ratio	0.87 ± 0.06	0.88 ± 0.06	< 0.001**	0.89 ± 0.06	< 0.001**
CD4 count (/mL)	150.86 ± 67.32	210.45 ± 35.62	< 0.001**	361 ± 194.01	< 0.001**
Triglyceride (mg/dL)	178.46 ± 58.41	196.41 ± 64.44	< 0.001**	209.28 ± 71.34	< 0.001**
Total cholesterol (mg/dL)	171.17 ± 52.24	186.20 ± 53.37	< 0.001**	191.73 ± 53.68	< 0.001**
LDL cholesterol (mg/dL)	108.62 ± 38.67	122.26 ± 38.29	< 0.001**	126.78 ± 39.74	< 0.001**
VLDL cholesterol (mg/dL)	35.69 ± 11.76	39.28 ± 12.93	< 0.001**	41.85 ± 14.43	< 0.001**
HDL cholesterol (mg/dL)	26.86 ± 12.69	24.66 ± 11.58	< 0.001**	23.10 ± 11.44	< 0.001**

Table 2. Anthropometric and Biochemical Parameters of the HIV-Positive Patients

Parameter

Treatment-naive HIV-positive patients

3 months on HAART

P value

6 months on HAART

P value

*Significant; **Highly significant; all values are in mean ± SD.

Number of patients

100

Weight (kg)

51.41 ± 9.95

54.14 ± 10.23

< 0.001**

54.78 ± 9.75

< 0.001**

BMI (kg/m²)

23.27 ± 4.21

24.21 ± 3.25

< 0.001**

25.61 ± 3.89

< 0.001**

Waist circumference (cm)

70.57 ± 7.88

72.29 ± 8.15

< 0.001**

72.97 ± 8.16

< 0.001**

Hip circumference (cm)

81.03 ± 7.34

81.95 ± 7.56

< 0.001**

82.04 ± 7.42

< 0.001**

Waist/hip ratio

0.87 ± 0.06

0.88 ± 0.06

< 0.001**

0.89 ± 0.06

< 0.001**

CD4 count (/mL)

150.86 ± 67.32

210.45 ± 35.62

< 0.001**

361 ± 194.01

< 0.001**

Triglyceride (mg/dL)

178.46 ± 58.41

196.41 ± 64.44

< 0.001**

209.28 ± 71.34

< 0.001**

Total cholesterol (mg/dL)

171.17 ± 52.24

186.20 ± 53.37

< 0.001**

191.73 ± 53.68

< 0.001**

LDL cholesterol (mg/dL)

108.62 ± 38.67

122.26 ± 38.29

< 0.001**

126.78 ± 39.74

< 0.001**

VLDL cholesterol (mg/dL)

35.69 ± 11.76

39.28 ± 12.93

< 0.001**

41.85 ± 14.43

< 0.001**

HDL cholesterol (mg/dL)

26.86 ± 12.69

24.66 ± 11.58

< 0.001**

23.10 ± 11.44

< 0.001**

**Table 3.** Percentage of Patients With Dyslipidemia Before and After 6 Months of HAART
Parameter	Treatment-naive patients	After 6 months of HAART	P value
Significant; *Highly significant.
TC (> 230 mg/dL)	8%	12%	< 0.001**
TG (> 160 mg/dL)	29%	52%	< 0.001**
LDL-C (> 160 mg/dL)	7%	9%	< 0.001**
VLDL-C (> 32 mg/dL)	23%	48%	< 0.001**
HDL-C (< 30 mg/dL)	10%	33%	< 0.001**

Table 3. Percentage of Patients With Dyslipidemia Before and After 6 Months of HAART

Parameter

Treatment-naive patients

After 6 months of HAART

P value

*Significant; **Highly significant.

TC (> 230 mg/dL)

12%

< 0.001**

TG (> 160 mg/dL)

29%

52%

< 0.001**

LDL-C (> 160 mg/dL)

< 0.001**

VLDL-C (> 32 mg/dL)

23%

48%

< 0.001**

HDL-C (< 30 mg/dL)

10%

33%

< 0.001**